focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 250.00
Bid: 240.00
Ask: 260.00
Change: 10.00 (4.17%)
Spread: 20.00 (8.333%)
Open: 238.00
High: 257.00
Low: 238.00
Prev. Close: 240.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Quiz sales fall, names new CEO; Byotrol eyes AIM exit

Wed, 03rd Apr 2024 10:59

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Quiz PLC - Glasgow, Scotland-based fashion retailer - Chief Executive Officer Tarak Ramzan, who also founded Quiz and is largest shareholder, steps down from post. He takes on a non-executive director role. Chief Commercial Officer Sheraz Ramzan takes over as CEO immediately. "He will implement a turnaround strategy to recalibrate the Quiz brand, its product offering, and reconnect with consumers with the aim of moving the business back into profitable growth," the firm says. Non-Executive Chair Peter Cowgill to take a "more active role in supporting the Company through to conclusion of the ongoing review of strategic options". Cowgill was formerly executive chair of JD Sports Fashion PLC. Quiz adds: "In addition to these changes, the board continues to search for at least one additional independent non-executive director following Charlotte O'Sullivan's departure in November 2023 and will provide an update in due course." Quiz says UK sales continue to be "impacted by subdued levels of traffic both in-store and online". Between the start of 2024 up to February 29, sales fell 9% on-year to GBP8.6 million. Sales since the start of the financial year on April 1 until the end of February fell 12% annually to GBP74.4 million. Expects revenue and a pretax loss in line with expectations. Quiz adds: "The group is taking a number of positive steps to counter the impact of the declining revenues including targeting cost savings for the forthcoming year, eliminating loss making activities, reviewing operational efficiencies and optimising its product offer."

----------

Byotrol PLC - manufacturer of biocidal and antimicrobial cleaning products - Proposes cancellation of AIM listing and re-registration as private company, as its directors conclude that it is no longer financially viable to continue trading shares publicly. In a trading update, Byotrol says it expects product sales in the financial year ending Sunday to be in line with expectations at GBP3.9 million, up 5.4% from GBP3.7 million a year earlier on a like-for-like basis, excluding discontinued items. It now expects headline loss before interest, tax, depreciation and amortisation, before exceptionals, of GBP1.0 million, widening from GBP700,000 a year earlier.

----------

Molecular Energies PLC - North, Central and South America-focused oil and gas company - Proposes cancelling its listing on AIM in London, saying it can no longer justify the "disproportionately high costs"."I take no joy in recommending the cancellation of trading in Molecular's shares on AIM and know that this proposal will impact many shareholders. However, the primary benefits of being listed are to avail oneself of access to capital, the ability to utilise one's shares as currency and enjoying the reputational boost of being on the London Stock Exchange. Molecular no longer receives any of those benefits," says Chair Peter Levine. "As a group its interests are best served by turning to the private arena where Molecular can regenerate away from the microscope and constraints of the public markets yet avail itself of funding and exit opportunities in some ways more flexible and abundant than remaining as a small public company on the London market." Reconsiders merit of float of 75% owned carbon removal and mitigation subsidiary Green House Capital Group PLC but believes the IPO is not in the "best interests of the company or its shareholders at the current time". Shareholders to vote on Molecular's delisting proposal on April 15. The last day of dealings could be April 26.

----------

Hellenic Dynamics PLC - Cultivator and supplier of medical cannabis products with a facility in northern Greece - Riverfort Securities Ltd subscribes for shares in Hellenic in order to discharge part of an outstanding loan to the medical cannabis cultivator. The loan and accrued interest of GBP90,757 will be settled through the issue of 3.9 million shares at 2.34 pence each.

----------

Provexis PLC - Reading, England-based producer of heart-health functional food ingredient Fruitflow - Agrees purchase of further batch of Fruitflow II SD inventory from dsm-firmenich, to satisfy increasing demand. Purchase totals GBP341,000. Provexis issues 45.1 million new shares, worth GBP293,304, to dsm-firmenich to part satisfy purchase. Rest of consideration to be satisfied in cash. "The Company is also pleased to confirm that it has now completed the setup of a new Irish subsidiary company, Provexis Ireland Ltd, which will facilitate tariff free sales of Fruitflow to customers in the EU," Provexis adds.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based drug discovery and development company - Says in advanced talks with "various investors in order to secure immediate funding". "The company's current cash balance is sufficient to allow the Faron to continue its operations into April 2024, however whilst the company is in advanced negotiations to complete the remaining bridge financing of approximately EUR5 million shortly, the Company notes that there is no guarantee that the required funds will be raised," Faron adds.

----------

Real Estate Credit Investments Ltd - investor in European real estate credit markets - Plans further buyback programme which runs to September 30 worth GBP10.0 million in total. Initial buyback of GBP5.0 million had expired at end of March.

----------

Coro Energy PLC - South East Asian-focused energy company - Notes announcement from Conrad Asia Energy Ltd, holder of 77% interest in Duyung production sharing contract in offshore Indonesia. Conrad announces gas sales agreement for domestic portion of Mako gas to Indonesia's national oil company PT Pertamina. Coro has a 15% stake in the production sharing pact. Empyrean Energy PLC, with an 8.5% interest, also notes the announcement. Both also note a new reserves report for Duyung. Revised estimate of best case recoverable dry gas as of December 31 stands at 329 billion cubic feet. This is a 10% decrease from a July 2022 report.

----------

San Leon Energy PLC - Nigeria-focused oil and gas production, development and exploration company - Notes Decklar Petroleum Ltd announces Crude oil volumes from Oza field through Trans Niger pipeline to Bonny export terminal. Just over 18,400 barrels of crude oil transported so far in 2024. "Decklar and Millenium have injected a total of 34,600 barrels of crude oil into the Bonny Export Terminal from commencement of TNP pipeline operation in late 2023," San Leon adds. It has an 11% shareholding in Decklar.

----------

Global Connectivity PLC - Isle of Man-based broadband provider to rural areas in the UK - Changes terms of warrants attached to shares subscribed for at time of initial public offering back in October 2020. Extends warrant exercise period by two years to April 20, 2026 for 100.0 million investor warrants and cuts exercise price to 1.5p per share. For 1.6 million adviser warrants, which had been due to expire in October 2025, the exercise period is also extended to April 2026 and also at 1.5p per share. Executive Chair Keith Harris says: "In recognition of the support offered to us by investors and other stakeholders at the stage of our initial listing, your board has decided to improve the terms of the warrants issued at that time as described above. We continue to explore other potential investments in companies in the communication services space and technologies that enhance connectivity."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
31 Oct 2022 19:58

TRADING UPDATES: 4Global wins deal; James Cropper profit warning

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
14 Oct 2022 11:14

Faron Pharmaceuticals shares down as raises EUR8.4 million in placing

(Alliance News) - Faron Pharmaceuticals Ltd shares declined on Friday, after it said it has raised EUR8.4 million from a share placing.

Read more
13 Oct 2022 21:17

TRADING UPDATES: Bidstack names new COO; Fintel expands deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 12:10

REPEAT: Faron Pharma half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
25 Aug 2022 11:43

Faron Pharmaceuticals half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
18 Aug 2022 16:02

UK earnings, trading statements calendar - next 7 days

Friday 19 August 
Apax Global Alpha LtdHalf Year Results
Kingspan Group PLCHalf Year Results
Newcrest Mining LtdFull Year Results
Monday 22 August 
Smoove PLCFull Year Results
Tuesday 23 August 
Aferian PLCHalf Year Results
John Wood Group PLCHalf Year Results
Wednesday 24 August 
Costain Group PLCHalf Year Results
Lookers PLCHalf Year Results
Standard Chartered PLCHalf Year Results
Thursday 25 August 
Amigo Holdings PLCQ1 Results
Anglo Pacific Group PLCHalf Year Results
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
Grafton Group PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Morses Club PLCFull Year Results
South32 LtdFull Year Results
  
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
30 Jun 2022 15:59

UK shareholder meetings calendar - next 7 days

Friday 1 July 
All Star Minerals PLCGM re name change to Marula Mining
Monday 4 July 
Active Energy Group PLCAGM
Clean Invest Africa PLCAGM
Securities Trust of Scotland PLCAGM
Tuesday 5 July 
Immediate Acquisition PLCAGM
Marks & Spencer Group PLCAGM
Open Orphan PLCAGM
Saga PLCAGM
Smartspace Software PLCAGM
Young & Co's Brewery PLCAGM
Wednesday 6 July 
Assura PLCAGM
ContourGlobal PLCGM re acquisition by KKR
GSK PLCGM re Consumer Healthcare demerger, Haleon listing
Mining Minerals & Metals PLCAGM
PCF Group PLCGM re director allotment authority
Puma Alpha VCT PLCAGM
Shires Income PLCAGM
Sirius Real Estate LtdAGM
Strategic Minerals PLCAGM
Worldwide Healthcare Trust PLCAGM
Thursday 7 July 
C&C Group PLCAGM
Distil PLCAGM
Emmerson PLCAGM
Faron Pharmaceuticals LtdGM re issuance of shares
FD Technologies PLCAGM
Great Portland Estates PLCAGM
Greencare Capital PLCAGM
J Sainsbury PLCAGM
JPMorgan European Growth & Income PLCAGM
Land Securities Group PLCAGM
Likewise Group PLCGM re approval of waiver by takeover/merger panel
N Brown Group PLCAGM
Octopus Apollo VCT PLCAGM
Peel Hunt LtdAGM
Pets At Home Group PLCAGM
Puma VCT 13 PLCAGM
Severn Trent PLCAGM
TomCo Energy PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
28 Jun 2022 18:03

IN BRIEF: Faron raises EUR5 million for bexmarilimab development

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset.

Read more
15 Jun 2022 19:24

IN BRIEF: Faron Pharma reveals topline results from MATINS trial

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts.

Read more
8 Jun 2022 16:54

IN BRIEF: Faron Pharma doses first patient in bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains.

Read more
16 May 2022 17:35

IN BRIEF: US and Finland approve Faron's bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab.

Read more
12 May 2022 19:45

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Apr 2022 19:30

IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday.

Read more
5 Apr 2022 20:45

TRADING UPDATES: Rambler ups production; SRT Marine anticipates loss

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
25 Mar 2022 13:21

EARNINGS UPDATES: Everyman revenue doubles; Aeorema in interim profit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.